Feb 5, 2021
[< 1 min Read]
Just based on a general analysis, REGN is lagging behind its peers in the pharmaceuticals industry. Retail traders may be avoiding this stock due to the high price, but there's are a ton of core fundamentals that are supporting this stock. First in terms of volatility and overpricing in the market, REGN is slightly undervalued even with a P/E ratio of 16.74. REGN has not benefited from a coronavirus push as much due to their focus on other pharmaceutical products, but even then so their sales have increased YoY. https://www.cnbc.com/2021/02/05/regeneron-pharmaceuticals-regn-q4-2020-earnings.html
Looking to put a bit of fund into REGN as a long term hold. They are a relatively stable company with good room for growth.